Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
173
-
Total 13F shares, excl. options
-
81.1M
-
Shares change
-
+12.7M
-
Total reported value, excl. options
-
$1.53B
-
Value change
-
+$232M
-
Put/Call ratio
-
0.13
-
Number of buys
-
92
-
Number of sells
-
-76
-
Price
-
$18.84
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q4 2024
207 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 173 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.1M shares
.
Largest 10 shareholders include FMR LLC (10.6M shares), BlackRock, Inc. (7.68M shares), VANGUARD GROUP INC (4.35M shares), Redmile Group, LLC (4.19M shares), BAKER BROS. ADVISORS LP (3.88M shares), WELLINGTON MANAGEMENT GROUP LLP (3.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.01M shares), Deep Track Capital, LP (3M shares), COMMODORE CAPITAL LP (3M shares), and STATE STREET CORP (2.8M shares).
This table shows the top 173 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.